Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Bredemeier

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 29, 2017
Comments on Mignot et al.: bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture riskMarkus Bredemeier
Arthritis Care & Research|June 7, 2014
Reply: To PMID 23983134Markus Bredemeier
Annals of the Rheumatic Diseases|October 7, 2020
Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'Markus Bredemeier
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2018
Mounting Evidence Indicates That Escalating Doses of Allopurinol Are Unnecessary for Cardiovascular Protection: Comment on the Article by Coburn et alMarkus Bredemeier
Arthritis and Rheumatism|April 12, 2012
Last observation carried forward approach threatens the validity of intent-to-treat analysis in fibromyalgia trials: comment on the article by Arnold et alMarkus Bredemeier
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2021
Clinical and Methodologic Considerations With Regard to a Trial of Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Comment on the Reanalysis by Maher et alMarkus Bredemeier
Arthritis & Rheumatology (Hoboken, N.J.)|October 6, 2021
Additional points to consider before incorporating the Food and Drug Administration-approved therapies for systemic sclerosis-associated interstitial lung disease: comment on the article by Khanna et alMarkus Bredemeier
Arthritis and Rheumatism|July 3, 2010
A higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: comment on the article by Seibold et alMarkus Bredemeier
Annals of the Rheumatic Diseases|October 13, 2017
How useful is PET/CT in the evaluation of fever/inflammation of unknown origin? Comment on the article by Schönau <i>et al</i>Markus Bredemeier
Journal of Hypertension|December 3, 2019
Adverse cardiovascular effects of allopurinol are related to the use of high dosesMarkus Bredemeier
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 29, 2017
Comments on Mignot et al.: bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture riskMarkus Bredemeier
Arthritis Care & Research|June 7, 2014
Reply: To PMID 23983134Markus Bredemeier
Annals of the Rheumatic Diseases|October 7, 2020
Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'Markus Bredemeier
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2018
Mounting Evidence Indicates That Escalating Doses of Allopurinol Are Unnecessary for Cardiovascular Protection: Comment on the Article by Coburn et alMarkus Bredemeier
Arthritis and Rheumatism|April 12, 2012
Last observation carried forward approach threatens the validity of intent-to-treat analysis in fibromyalgia trials: comment on the article by Arnold et alMarkus Bredemeier
Arthritis & Rheumatology (Hoboken, N.J.)|June 9, 2021
Clinical and Methodologic Considerations With Regard to a Trial of Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Comment on the Reanalysis by Maher et alMarkus Bredemeier
Arthritis & Rheumatology (Hoboken, N.J.)|October 6, 2021
Additional points to consider before incorporating the Food and Drug Administration-approved therapies for systemic sclerosis-associated interstitial lung disease: comment on the article by Khanna et alMarkus Bredemeier
Arthritis and Rheumatism|July 3, 2010
A higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: comment on the article by Seibold et alMarkus Bredemeier
Annals of the Rheumatic Diseases|October 13, 2017
How useful is PET/CT in the evaluation of fever/inflammation of unknown origin? Comment on the article by Schönau <i>et al</i>Markus Bredemeier
Journal of Hypertension|December 3, 2019
Adverse cardiovascular effects of allopurinol are related to the use of high dosesMarkus Bredemeier
Pageof 6